Cat. No. 5582
Biological ActivitySelective HIF-1 dimerization inhibitor. Blocks protein-protein interaction of recombinant HIF-1α, but not HIF-2α, with HIF-1β (IC50 = 1.3 μM) . Inhibits hypoxia-induced HIF-1 activity, and decreases VEGF and CAIX expression in osteosarcoma and breast cancer cells in vitro. Also reduces tubularization of hypoxic HUVECs.
(Modifications: Lactam bridge: Cys-1 to Tyr-6), Disulfide bridge: 1-1*)
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Miranda et al (2013) A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. J.Am.Chem.Soc. 135 10418. PMID: 23796364.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses TAT-cyclo-CLLFVY from Tocris? If so please let us know.
View Related Products by Product Action
Keywords: TAT-cyclo-CLLFVY, supplier, HIF-1a, 1b, 1beta, 1alpha, α, β, hypoxia, inducible, factor, cancer, angiogenesis, antiangiogenic, dimerization, inhibitors, inhibits, Tocris Bioscience, Hypoxia Inducible Factor Inhibitor products
Find multiple products by catalog number
New Products in this Area
Gene switch ligand for use in induceable gene expression systemsML 334
Inhibitor of Keap1- Nrf2 interactionRA 839
Nrf2 activator; inhibits Nrf2/Keap1 interactionGN 44028
Potent HIF-1α inhibitor
Follow @Tocris on Twitter
Tocris is now actively tweeting. For regular updates on news, events and special offers, follow @Tocris on Twitter.